Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6680055 | 0.69 | ALDH1A1 (0.41) | TYMSMAPK1ATMKDM4EALDH1A1 | |
| SCHEMBL218834 | 0.68 | TRPA1 (0.36) | MAPK1ATMKDM4ECYP1A2TRPA1 | |
| SCHEMBL3422460 | 0.65 | ALDH1A1 (0.38) | TYMSMAPK1ATMKDM4EALDH1A1 | |
| SCHEMBL4049789 | 0.62 | ALDH1A1 (0.39) | MAPK1ATMKDM4EALDH1A1TSHR | |
| SCHEMBL2637178 | 0.62 | GRK6 (0.45) | KDM4EALDH1A1TSHRHSD17B10CYP1A1 | |
| SCHEMBL29473502 | 0.62 | GRK6 (0.45) | KDM4EALDH1A1TSHRHSD17B10CYP1A1 | |
| SCHEMBL27705122 | 0.61 | MAPK1 (0.65) | TYMSMAPK1ATMKDM4EALDH1A1 | |
| SCHEMBL18440765 | 0.60 | ALDH1A1 (0.36) | MAPK1ATMALDH1A1TSHRHSD17B10 | |
| SCHEMBL2771008 | 0.58 | TSHR (0.41) | TYMSMAPK1ATMKDM4EALDH1A1 | |
| SCHEMBL752653 | 0.58 | GRK6 (0.37) | MAPK1KDM4EALDH1A1TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252814-B2 | Agents and crystals for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-28 | — | — | US | disclosed |
| US-20090264467-A1 | Agents and crystals for improving excretory potency of urinary bladder | ISHIHARA YUJI | 2009-10-22 | — | — | US | disclosed |
| US-7462628-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-09 | — | — | US | disclosed |
| EP-1891954-A2 | Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder | Takeda Pharmaceutical Company Limited (JP) | 2008-02-27 | — | — | EP | disclosed |
| US-20070232538-A1 | Uses of polypeptides | TAKEDA PHARMACEUTICAL COMPANY, LTD (JP) | 2007-10-04 | — | — | US | disclosed |
| US-20070027138-A1 | Derivatives and analogs of galanthamine | SANOCHEMIA PHARMAZEUTIKA AKTIENGESELLSCHAFT | 2007-02-01 | — | — | US | disclosed |
| US-20070021391-A1 | Preventive/remedy for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-25 | — | — | US | disclosed |
| US-7166588-B2 | Derivatives and analogs of galanthamine | SANOCHEMIA PHARMAZEUTIKA AKTIENGESELLSCHAFT (AT) | 2007-01-23 | — | — | US | disclosed |
| US-20060281725-A1 | Agents and crystals for improving excretory potency of urinary bladder | ISIHARA YUJI | 2006-12-14 | — | — | US | disclosed |
| US-7138533-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-21 | — | — | US | disclosed |
| US-5527800-A | A 4H-PYRROLO(3,2,1-IJ)QUINOLIN-8-YL DERIVATIVE ADMINISTERED FOR THERAPY OR PROPHYLAXIS OF SENILE DEMENTIA | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-06-18 | — | — | US | disclosed |
| EP-0607864-A2 | Tricyclic condensed heterocyclic compounds for the treatment of senile dementic | Takeda Chemical Industries, Ltd. (JP) | 1994-07-27 | — | — | EP | disclosed |
| EP-0377889-B1 | Silver halide recording material | AGFA GEVAERT AG (DE) | 1994-05-18 | — | — | EP | disclosed |
| EP-0373339-B1 | Silver halide recording material | AGFA GEVAERT AG (DE) | 1994-05-04 | — | — | EP | disclosed |
| US-5089381-A | SILVER HALIDE RECORDING MATERIAL | AGFA-GEVAERT AG (DE) | 1992-02-18 | — | — | US | disclosed |
| EP-0377889-A1 | Silver halide recording material | Agfa-Gevaert AG (DE) | 1990-07-18 | — | — | EP | disclosed |
| EP-0373339-A1 | Silver halide recording material | Agfa-Gevaert AG (DE) | 1990-06-20 | — | — | EP | disclosed |
| US-4906557-A | Photographic recording material and process for the production of photographic images | AGFA-GEVAERT AKTIENGESELLSCHAFT (DE) | 1990-03-06 | — | — | US | disclosed |
| US-4820616-A | STABILIZERS, ANTIFOGGING AGENTS | AGFA-GEVAERT AKTIENGESELLSCHAFT (DE) | 1989-04-11 | — | — | US | disclosed |
| EP-0234392-A2 | Photographic-recording material and process for making photographic images | Agfa-Gevaert AG (DE) | 1987-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021391-A1 | Preventive/remedy for urinary disturbance | ACHE, BCHE, CHAT | TYMS 1647/4885MAPK1 3860/4885ATM 3255/4885 |
| US-20070027138-A1 | Derivatives and analogs of galanthamine | GALR2, GALR1, GALR3 | TYMS 1528/4885MAPK1 1269/4885ATM 4276/4885 |
| US-20090264467-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BCHE, PDE7A | TYMS 1011/4885MAPK1 2350/4885ATM 4289/4885 |
| US-20070232538-A1 | Uses of polypeptides | NPSR1, SCTR, GRPR | TYMS 4356/4885MAPK1 2089/4885ATM 4118/4885 |
| US-20060281725-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BCHE, PDE7A | TYMS 853/4885MAPK1 2209/4885ATM 4375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.